Search results
Results from the WOW.Com Content Network
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.
Digital rectal examination (DRE), also known as a prostate exam (Latin: palpatio per anum (PPA), lit. 'palpation through the anus'), is an internal examination of the rectum performed by a healthcare provider .
Transrectal ultrasonography, or TRUS in short, is a method of creating an image of organs in the pelvis, most commonly used to perform an ultrasound-guided needle biopsy evaluation of the prostate gland in men with elevated prostate-specific antigen or prostatic nodules on digital rectal exam.
If the cancer has spread beyond the prostate, treatment options change significantly, so most doctors who treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, HIFU, external-beam radiation therapy, brachytherapy, cryosurgery, and surgery are, in general ...
The routine physical, also known as general medical examination, periodic health evaluation, annual physical, comprehensive medical exam, general health check, preventive health examination, medical check-up, or simply medical, is a physical examination performed on an asymptomatic patient for medical screening purposes.
Physicians with a Doctor of Medicine (MD) degree are required to pass the USMLE for medical licensure. However, those with a Doctor of Osteopathic Medicine degree (DO) are required to take the COMLEX-USA (COMLEX) exams but may also sit for the USMLE as well. [10] [11] States may enact additional testing and/or licensing requirements. [12]
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
In a study of young adults in Greece (aged 21–50, mean age 40.9 years), the prevalence was found to be 7.35%. [4] While among urologic patients in South Korea (aged 29–89, mean age 61.9 years), the prevalence was 40.7%. [5] The prevalence is notably higher in patients with benign prostatic hyperplasia, ranging from 68.8% to 70%. [3]